Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label rollover study of dabrafenib and/or trametinib in pediatric patients with BRAF V600-mutant advanced solid tumors
MOH_2022-10-18_011964Phase 4Recruiting
- Sponsor
- Novartis
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dabrafenib + trametinib and trametinib in Nonhematologic neoplasms, sponsored by Novartis. Started Sep 2022; status: recruiting.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on MOH_2022-10-18_011964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-10-18_011964.